Merck & Co Closing In On Seagen Acquisition
Deal Expected To Be Worth Around $38bn
Merck is closing in on the acquisition of the antibody drug conjugate specialists which would help the pharma giant consolidate its presence in oncology.
You may also be interested in...
The blockbuster PD-1 inhibitor and antibody-drug conjugate will be used to treat a subset of first-line urothelial carcinoma patients considerably widening Padcev’s market, but rates of peripheral neuropathy with the combination have left some analysts concerned.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.